%0 Journal Article %A A Lerch %A QA ten Bosch %A M L’Azou Jackson %A AA Bettis %A M Bernuzzi %A GAV Murphy %A QM Tran %A JH Huber %A AS Siraj %A M Elliott %A C Hartlage %A K Koh %A K Strimbu %A M Walters %A TA Perkins %A SM Moore %T Projecting vaccine demand and impact for emerging zoonotic pathogens %D 2021 %R 10.1101/2021.11.09.21266135 %J medRxiv %P 2021.11.09.21266135 %X Despite large outbreaks in humans seeming improbable for a number of zoonotic pathogens, several pose a concern due to their epidemiological characteristics and evolutionary potential. To enable effective responses to these pathogens in the event that they undergo future emergence, the Coalition for Epidemic Preparedness Innovations is advancing the development of vaccines for several pathogens prioritized by the World Health Organization. A major challenge in this pursuit is anticipating demand for a vaccine stockpile to support outbreak response. We developed a modeling framework for outbreak response for emerging zoonoses under three reactive vaccination strategies. Annual vaccine regimen requirements for a population-wide strategy ranged from >670,000 (95% prediction interval: 0-3,630,000) for Lassa virus to 1,190,000 (95% PrI: 0-8,480,000) for Rift Valley fever virus, while the regimens required for ring vaccination or targeting healthcare workers (HCWs) were several orders of magnitude lower. For each pathogen and vaccination strategy, reactive vaccination typically prevented fewer than 10% of cases, because of their presently low R0 values. Targeting HCWs had a higher per-regimen impact than population-wide vaccination. Our framework provides a flexible methodology for estimating vaccine stockpile needs and the geographic distribution of demand under a range of outbreak response scenarios.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe following authors were supported by a contract from CEPI to the University of Notre Dame: AL, QAtB, QMT, JHH, ASS, ME, CH, KK, KS, MW, TAP, SMM.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data used in the present study were obtained from public sources and cited in the manuscript. The collated data, along with code to run our model, are provided at https://github.com/lerch-a/CEPI_VaccineCampaignGUI. https://github.com/lerch-a/CEPI_VaccineCampaignGUI %U https://www.medrxiv.org/content/medrxiv/early/2021/11/10/2021.11.09.21266135.full.pdf